通过导管结构性心脏干预后与抗血栓治疗相关的出血和血栓风险的审查
Hideyuki Kawashima1, Yohei Numasawa2, Naoki Hayakawa3
1Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
JACC. Asia
|January 15, 2024
概括
通过导管进行的结构性心脏干预需要在手术后进行抗血栓治疗,因为存在血栓塞的风险. 在高风险患者中平衡这种治疗与出血风险是一个关键的挑战.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 生物材料是一种生物材料.
背景情况:
- 过导管结构性心脏干预已经取得了显著的进步.
- 在这些程序中部署设备会导致血栓粘附,需要抗血栓治疗.
- 术后出血并发症由抗血栓药物是越来越令人担忧的.
研究的目的:
- 通过导管结构性心脏干预后审查当前的抗血栓策略.
- 为了评估接受这些手术的患者的出血风险.
- 确定高血栓和出血风险患者的抗血栓治疗管理方面的挑战.
主要方法:
- 关于抗血栓治疗的最新研究的文献综述.
- 对出血风险评估工具和结果的分析.
- 专注于通过导管的动脉置换,边缘到边缘的修复,以及左心房附属物阻塞.
主要成果:
- 抗血栓治疗是标准的,但与显著的出血风险相关.
- 患者往往同时存在高血栓和出血风险.
- 最佳的抗血栓治疗方案,平衡有效性和安全性仍然具有挑战性.
结论:
- 谨慎的患者选择和风险分层对于抗血栓治疗至关重要.
- 需要进一步的研究来优化跨导管结构性心脏干预的抗血栓策略.
- 个性化抗血栓治疗方法可以减轻复杂患者群体的风险.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Disorders of Hemostasis
918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K


